CuraCell Signs Collaboration Agreement with Zellwerk-Berlin

October, 2022

Takura’s affiliate CuraCell signes collaboration agreement with Zellwerk-Berlin, a Specialized Contract Development & Manufacturing Organization (CDMO) with engagements in Tumor Infiltrating Lymphocytes (TIL), Natural Killer (NK) cells and Mesenchymal Stromal Cells (MSC), an affiliate of Hiper Group. CuraCell acquires intellectual property rights from Zellwerk Berlin associated with CuraCell’s TIL product, CC-38.

CC-38 has been used in patient named treatments in Germany demonstrating promising clinical results. The two companies will now join forces in optimizing and validating CC-38 for upcoming clinical trials. Through the collaboration CuraCell gets access to process engineering capabilities of Zellwerk Berlin’s R&D team and secures manufacturing capacity for its first clinical phase.